Molecular Testing of Lung Cancers
Journal of Pathology and Translational Medicine
;
: 242-254, 2017.
Article
Dans Anglais
| WPRIM
| ID: wpr-38101
ABSTRACT
Targeted therapies guided by molecular diagnostics have become a standard treatment of lung cancer. Epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as the best predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively. Besides EGFR and ALK, the list of druggable genetic alterations has been growing, including ROS1 rearrangements, RET rearrangements, and MET alterations. In this situation, pathologists should carefully manage clinical samples for molecular testing and should do their best to quickly and accurately identify patients who will benefit from precision therapeutics. Here, we grouped molecular biomarkers of lung cancers into three categories—mutations, gene rearrangements, and amplifications—and propose expanded guidelines on molecular testing of lung cancers.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Phosphotransferases
/
Protein-tyrosine kinases
/
Marqueurs biologiques
/
Réarrangement des gènes
/
Médecine de précision
/
Anatomopathologie moléculaire
/
Récepteurs ErbB
/
Poumon
/
Tumeurs du poumon
/
Lymphomes
Type d'étude:
Etude diagnostique
/
Guide de pratique
/
Étude pronostique
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Journal of Pathology and Translational Medicine
Année:
2017
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS